This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PCORI Awards $88.6 Million In Funding For Comparative Effectiveness Research Projects

CHICAGO, May 7, 2013 /PRNewswire-USNewswire/ -- The Patient-Centered Outcomes Research Institute (PCORI) has approved 51 new awards, totaling $88.6 million over three years, to fund patient-centered comparative clinical effectiveness research (CER) projects under the first four areas of its National Priorities for Research and Research Agenda. This brings the total that PCORI has awarded for projects addressing these priorities to $129.3 million. PCORI also has committed another $30 million in funding for a series of pilot projects.

The projects approved Monday May 6 during a public meeting of PCORI's Board of Governors include studies of how to best care for people with kidney disease, certain cancers, obesity, asthma, diabetes, and various mental health conditions. Other projects will explore ways to support patient decision-making, reduce specific health disparities, and improve health care delivery systems.  

"PCORI and our merit reviewers believe that patients and those who care for them will greatly benefit from the comparative information these projects will provide," said PCORI Executive Director Joe Selby, MD, MPH. "We're very pleased that we were able to double the amount of research awarded in our inaugural funding cycle thanks to the number of high-quality proposals we received. We look forward to working with researchers, patients, caregivers, clinicians and others within the healthcare community, to build a robust portfolio of patient-centered, comparative effectiveness research."

The awards are part of PCORI's second cycle of primary research funding, which opened for submissions in September 2012, and were selected from among more than 400 completed applications.  All were approved by the Board pending completion of a business and programmatic review by PCORI staff and completion of a formal award contract.

This latest round of awards, like the initial round announced in December 2012, are based on the broad set of PCORI Funding Announcements (PFAs) released the previous May.

The approved projects were selected through a competitive review process in which scientists, patients, caregivers, and other stakeholders helped to evaluate proposals on the basis of scientific merit, how well they engage patients and other stakeholders, their methodological rigor, and how well they fit within PCORI's national research priorities.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs